rs622342A>C in SLC22A1 is associated with metformin pharmacokinetics and glycemic response |
| |
| Affiliation: | 1. Department of Biological Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon;2. Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon;1. Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-Aoba, Aoba-ku, Sendai 980-8578, Japan;2. Food Safety Commission, Cabinet Office, Government of Japan, Akasaka Park Bld., Tokyo, 107-6122, Japan;3. Division of Risk Assessment, National Institute of Health Sciences, Tonomachi 3-25-26, Kawasaki, Kanagawa, 210-9501, Japan;4. Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526 Japan;1. Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd, Kainan, Japan;2. Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima-city, Japan;3. Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Japan;1. Clinical Pharmacology & Pharmacokinetics, Project Management Department, Shionogi & Co., Ltd, Japan;2. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Japan |
| |
| Abstract: | Polymorphisms in SLC22A1 lead to variability in metformin clinical efficacy. Sixty-three Lebanese patients with type 2 diabetes who administered metformin, were followed up for six months and genotyped for rs622342A>C. The area under the plasma concentration-time curve and the maximum concentration of metformin was highest in CC patients (P ≤ 0.03). There was a significant difference between groups in the percentage decrease in fasting blood sugar (FBS) and glycated hemoglobin (HbA1c). Going into the same direction, rs622342C was associated with decrease in FBS levels after three and six months of treatment (P ≤ 0.02), whereas with HbA1c, the decrease was noticed after six months (β = −2.78; P = 0.03). In contrast, the serum levels of lactate and creatinine did not vary significantly according to rs622342A>C genotypes.The rs622342A>C in SLC22A1 may be associated with metformin pharmacokinetics and variability in therapeutic efficacy. |
| |
| Keywords: | Type 2 diabetes mellitus Metformin pharmacokinetics rs622342A>C |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
